Table 1.
Patients’ characteristics.
| Variable | Patients in the analysis (n = 243) | |
|---|---|---|
| N | % | |
| Age | ||
| Median (range) | 62 (24–84) | |
| Sex | ||
| Male | 100 | 41.15 |
| Female | 143 | 58.85 |
| Stage of tumor | ||
| Metastatic | 173 | 71.19 |
| Localized | 70 | 28.81 |
| Type of tumor | ||
| Lung | 41 | 16.87 |
| Breast | 51 | 20.99 |
| Gynecologic | 20 | 8.23 |
| Melanoma | 40 | 16.46 |
| NET | 9 | 3.7 |
| Sarcoma | 18 | 7.41 |
| Gastrointestinal | 17 | 7 |
| Head and neck | 11 | 4.53 |
| Genitourinary | 24 | 9.88 |
| Other | 12 | 4.94 |
| Treatment | ||
| Biological therapy | 106 | 43.62 |
| Chemotherapy | 62 | 25.51 |
| Chemotherapy + immunotherapy | 9 | 3.7 |
| RT/chemo + RT | 2 | 0.82 |
| Immunotherapy | 34 | 13.99 |
| Biological therapy + immunotherapy | 5 | 2.06 |
| None | 15 | 6.17 |
| – | 10 | 4.12 |
| Type of vaccine | ||
| mRNA-1273 | 126 | 51.85 |
| BNT162b2 | 117 | 48.15 |
NET, neuroendocrine tumor; RT, radiotherapy.